SCM
ALBO

Suvretta Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

Suvretta Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-80,900
Closed -$2.14M – 118
2020
Q2 		$2.14M Buy
80,900
+31,900
+65% +$752K 0.05% 72
2020
Q1 		$802K Buy
+49,000
New +$1.08M 0.02% 55

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Suvretta Capital Management's ALBO Position: Q3 2020 in Review

Suvretta Capital Management sold out of Albireo Pharma Inc (ALBO) in Q3 2020, closing a stake of 80,900 shares — an estimated $2.14M sold.

Suvretta Capital Management first reported a position in ALBO in Q1 2020 and held it in 2 quarters. The position peaked at $2.14M in Q2 2020. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2020.

  • Suvretta Capital Management reported no remaining Albireo Pharma Inc position as of Q3 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 80,900 Albireo Pharma Inc shares in Q3 2020, an estimated $2.14M.
  • Suvretta Capital Management first reported a position in Albireo Pharma Inc in Q1 2020 and held it in 2 quarters.
  • Suvretta Capital Management's Albireo Pharma Inc position peaked at $2.14M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2020.

Based on Suvretta Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.